Taysha Gene Therapies, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDTaysha Gene Therapies, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 73), indicating performance broadly in line with the market. Earnings contraction of 50% provides fundamental context to the price action. Investors should exercise caution due to high volatility (88% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.96 | +6.32% | ABOVE |
| 50 SMA | $6.13 | +3.38% | ABOVE |
| 100 SMA | $5.35 | +18.50% | ABOVE |
| 150 SMA | $5.25 | +20.87% | ABOVE |
| 200 SMA | $4.97 | +27.62% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TSHA in an uptrend right now?
TSHA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TSHA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TSHA overbought or oversold?
TSHA's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is TSHA outperforming the market?
TSHA has a Relative Strength (RS) Rating of 73 out of 99. TSHA is performing about average compared to the market.
Where is TSHA in its 52-week range?
TSHA is trading at $6.34, which is 87% of its 52-week high ($7.30) and 81% above its 52-week low ($2.25).
How volatile is TSHA?
TSHA has a Beta of 1.90 and 52-week volatility of 88%. It's more volatile than the S&P 500 - expect bigger swings.